New HSE toolkit on the use of sodium valproate (Epilim)

11th October 2016

The HSE has published a new toolkit on the drug Sodium Valproate (Epilim) for patients and prescribers.

The Valproate toolkit was produced by the National Clinical Programmes for Epilepsy, Mental Health and Medicines Management in consultation with the HPRA and patient groups.

It aims to reinforce the safety message for healthcare professionals and patients that valproate is not prescribed for girls or women of child-bearing age unless other treatments are not effective or are not tolerated.

In 2014, the European Medicines Agency strengthened its warnings on the use of valproate in women and girls due to the increased risk of developmental problems, autism and malformations in children exposed to valproate in the womb.

The online toolkit consists of:

  • Patient information booklet
  • Guidelines for prescribers
  • Patient/ Prescriber Checklist

Download the Patient Information booklet

valproate

 

 

 

 

 

For additional information on the toolkit, please visit the HSE website.

WARNING: The Migraine Association of Ireland is aware that Sodium Volproate has been and is currently prescribed for chronic migraine sufferers in Ireland. Sodium Valproate does not have a licence for the treatment of migraine in Ireland.  Prescription of this medicine for the treatment of migraine  is therefore an off label or out of license usage.  The manufacturers of Sodium Valproate, Sanofi, do not condone off label usage of any of their products. While Sanofi recognises that from time to time their medicines will be used in different ways out of license,  this usage is a prerogative of the prescribing physician. 

New HSE toolkit on the use of sodium valproate (Epilim)

11th October 2016

The HSE has published a new toolkit on the drug Sodium Valproate (Epilim) for patients and prescribers.

The Valproate toolkit was produced by the National Clinical Programmes for Epilepsy, Mental Health and Medicines Management in consultation with the HPRA and patient groups.

It aims to reinforce the safety message for healthcare professionals and patients that valproate is not prescribed for girls or women of child-bearing age unless other treatments are not effective or are not tolerated.

In 2014, the European Medicines Agency strengthened its warnings on the use of valproate in women and girls due to the increased risk of developmental problems, autism and malformations in children exposed to valproate in the womb.

The online toolkit consists of:

  • Patient information booklet
  • Guidelines for prescribers
  • Patient/ Prescriber Checklist

Download the Patient Information booklet

valproate

 

 

 

 

 

For additional information on the toolkit, please visit the HSE website.

WARNING: The Migraine Association of Ireland is aware that Sodium Volproate has been and is currently prescribed for chronic migraine sufferers in Ireland. Sodium Valproate does not have a licence for the treatment of migraine in Ireland.  Prescription of this medicine for the treatment of migraine  is therefore an off label or out of license usage.  The manufacturers of Sodium Valproate, Sanofi, do not condone off label usage of any of their products. While Sanofi recognises that from time to time their medicines will be used in different ways out of license,  this usage is a prerogative of the prescribing physician.